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INTRODUCTION
Hashimoto encephalopathy (HE) is an autoimmune 
disease that accompanies some cases of Hashimoto 
subacute thyroiditis (Seipelt et al., 1999). It some-
times  can  occur  independently.  Besides  HE,  the 
most commonly used name, this entity is also called 
steroid-responsive  encephalopathy  associated  with 
autoimmune thyroiditis (SREAT) and nonvasculitic 
autoimmune meningoencephalitis. As HE is imme-
diately recognizable, more than lengthy descriptive 
names, we will use the original name in this paper. 
Hashimoto thyroiditis (HT) has a prevalence of 8% 
of women, 3% of men, and 10% of women above 55 
years (Vanderpump and Tunbridge, 2002). The inci-
dence and prevalence of Hashimoto encephalopathy 
are not known but one study of unexplained enceph-
alopathies found a prevalence of 2.1/100,000 in the 
general population (Ferracci et al., 2004). There are 
no reports of familial Hashimoto’s encephalopathy.
Common in both HT and HE are the two main 
types  of  antibodies:  thyroglobulin  (TGAb)  and/or 
thyroxin peroxidase (TPOAb) or anti microsomal 
antibodies. The pathogenetic significance of these 
antibodies is not clear as their prevalence is high in 
normal  populations  (Chong  and  Rowland,  2006). 
The majority of patients are women (female to male 
ratio  4:  1)  (Ferracci  and  Carnevale,  2006).  This 
entity can be found in people of all ages from 8 to 
86 years (mean 46 years) (Ferracci and Carnevale, 
2006). In children there is no clear gender prepon-
derance (Mocellin et al., 2007). About one third of 
these patients are hypothyrotic.
Hashimoto  thyroiditis  is  an  autoimmune  thy-
roid  disease  characterized  by  the  destruction  of 
thyroid  cells  by  various  cell-  and  antibody-medi-
ated immune processes with slow progression over 
a  number  of  years.  It  is  primarily  a  histological 
diagnosis  first  described  by  Hakaru  Hashimoto, 
a  Japanese  surgeon  working  in  Berlin,  Germany 
(Hashimoto, 1912). He published a report, based on 
examination of the thyroid gland in four postopera-
tive cases, in 1912. 
The first description of HE dates back to 1966 
(Brain  et  al.).  The  patient,  who  had  Hashimoto 
thyroiditis and hypothyroidism, suffered 12 stroke-
like episodes with confusion over a year. He did not 
respond  to  corticosteroid  (prednisolone),  but  to 
thyroxin therapy alone. The next two patients were 
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described in 1974 (Thrush and Boddie). A woman 
who was euthyroid became depressed and developed 
recurrent seizures, myoclonus, and hallucinations. 
She was treated successfully with corticosteroids and 
cyclophosphamide. These patients inaugurated HE 
as a separate clinical entity, delineated the typical 
clinical pictures, and revealed efficacious therapy.
CLINICAL PICTURE
Clinical expression of HE is very diverse. The clas-
sical manifestations are: (1) occurrences of stroke-
like episodes and (2) a clinical picture mimicking 
Creutzfeldt-Jakob  disease  (CJD).  Patients  can  be 
euthyroid, hypothyroid, and even hyperthyroid with 
appropriate  signs  and  symptoms.  There  are  well-
documented cases of monosymptomatic illness with 
psychiatric  manifestations,  progressive  myelopa-
thy, dementia, seizures, paraesthesiae, or cerebellar 
symptoms (Ferracci and Carnevale, 2006).
Hashimoto encephalopathy
Encephalopathy can be the first clinical manifesta-
tion accompanying subclinical thyroiditis. The most 
frequent signs are epileptic seizures, subacute confu-
sion, myoclonus, cognitive impairment or demen-
tia, and disturbances of consciousness, all present 
in  more  than  40%  of  patients  each  (Ferracci  and 
Carnevale, 2006). Also there can be ataxia, tremor, 
personality disturbances, psychosis, hallucinations, 
sleep  abnormalities,  transient  aphasia,  pyramidal 
and/or  extrapyramidal  signs,  dysarrthria,  head-
ache, cerebellar symptoms, vertigo, myelopathy, and 
fatigue (Castillo et al., 2006; Ferracci and Carnevale, 
2006). So far, only one patient with HE has been 
found to be febrile with exclusion of other possible 
causes, and this patient responded well to corticoste-
roid therapy (Papathanasopoulos et al., 2000). One 
possible  explanation  is  that  tumor  necrosis  factor 
alpha, found in sera of patients with HT, acts as an 
endogenous pirogen.
Stroke-like episodes occur with focal neurologi-
cal signs, sometimes with seizures and impairment 
of consciousnes. This type is sometimes called the 
“vasculitic  type”.  The  CJD-like  presentation  with 
progressive cognitive impairment leading to demen-
tia,  with  psychotic  features  and  sometimes  with 
seizures, is also called the “diffuse progressive” type. 
In contrast to CJD, in HE there are no major visual 
disturbances, startle reactions, or rapid progression, 
but  there  are  fluctuations.  There  are  no  oligoclo-
nal bands or protein 14-3-3. There is an increased 
prevalence  of  lipid  disorders  in  association  with 
untreated hypothyroidism (which can cause vascu-
lar damage), so thyroid function tests are obligatory. 
High serum levels of antithyroid antibodies and a 
CJD-compatible clinical picture can mean not only 
HE, but sometimes a comorbidity.
Seizures  can  be  the  first  sign  of  HE  or  can 
develop later. The most common type of seizures 
is grand mal (78%), followed by simple partial or 
simple complex seizures with or without generaliza-
tion  (17%)  and  status  epilepticus  (13%)  (Ferracci 
and Carnevale, 2006). A rare case of a patient with 
psychosis and generalized absence status has been 
reported  (McKeon  et  al.,  2004).  Myoclonus  can 
occur in both major types of HE. Myoclonus can be 
focal or multifocal, spontaneous or action-triggered, 
and also of the reflex type (a startle response). 
In the progressive variety of HE, patients can 
suffer  from  dementia,  depression,  cerebellar,  and 
extrapyramidal symptoms (Ferracci and Carnevale, 
2006). Poor school performance is a frequent finding 
in children. Adults can have memory disturbances 
or progressive aphasia or apraxia corresponding to 
dementia. Some patients have fatigue.
Some  patients  become  somnolent,  and  con-
sciousness  can  deteriorate  to  coma.  Focal  neuro-
logical  deficits  can  be  motor  or  sensory.  Tremor 
can  be  found  in  almost  one  third  of  the  patients 
with characteristics of postural, action cerebellar, or 
rest tremors (Ferracci and Carnevale, 2006). There 
was a report of a patient with palatal tremor. Some 
patients have the presentation of Parkinsonism with 
rest tremor, hypokinesia, and rigidity. Chorea is a 
rare clinical presentation in HE. Some patients have 
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tiple system atrophy or progressive cerebellar ataxia 
(Nakagawa et al., 2007).
Neuropsychiatric symptoms and signs are fre-
quent, with psychosis, persecutory delusions, disor-
ganized speech, hallucinations (more of the visual 
type), and depression or elevated moods (Mocellin 
et al., 2007; Gómez-Bernal et al., 2007). Psychotic 
features can appear episodically and respond well 
to  corticosteroid  therapy  (Arrojo  et  al.,  2007). 
Personality disorders consist of anxiety, hyperemo-
tionality, outbursts of anger, violent behavior, para-
noia, and visual and auditory hallucinations. Some 
patients  can  have  only  psychiatric  and  not  neu-
rological  symptomatology  (Kinrys  and  Bostwick, 
2001). Such disease expression may mimic various 
psychiatric entities.
Contrary to hypothyroidism – where negative 
symptoms  prevail  with  psychomotor  retardation, 
apathy,  poor  attention,  somnolence,  and  lethargy 
(Doherty, 2005) – HE is characterized by a prepon-
derance  of  prominent  positive  symptomatology, 
such  as  mania,  psychosis,  seizures,  extrapyrami-
dal  rigidity,  myoclonus,  and  stroke-like  episodes 
(Chong et al., 2003).
Hashimoto myelopathy
Another clinical expression is spinal cord involve-
ment  or  Hashimoto  myelopathy  (Azuma  et  al., 
2000). A case was reported with primary involve-
ment of the spinal cord and brain two months later 
in the context of HT with a thoracic level of sensitiv-
ity. The immunological process was active no mat-
ter how well she was substituted with thyroxin, and 
relapses occurred even on steroid therapy. In this 
and two other described cases, MRI of the thoracic 
spine was inconspicuous. 
Thyroid function
Thyroid  function  does  not  significantly  influence 
the clinical picture of HE. Patients can have normal 
serum thyroxin and thyrotropin concentrations, and 
elevated  or  decreased  hormone  levels.  They  may 
have additional signs and symptoms of thyroid dys-
function and the majority are hypothyroid. In HE 
patients, subclinical hypothyroidism was found in 
35% of patients, overt hypothyroidism in 28%, sub-
clinical hyperthyroidism in 2%, and overt hyperthy-
roidism in 5%, and 22% of patients were euthyroid 
(Chong et al., 2003).
In  patients  with  hypothyroidism,  the  usual 
signs and symptoms are: fatigue, constipation, dry 
skin,  weight  gain  (mostly  due  to  fluid  accumula-
tion  in  interstitial  tissues),  cold  intolerance,  voice 
hoarseness,  slowed  movement  and  loss  of  energy, 
decreased sweating, mild nerve deafness, menstrual 
irregularities,  galactorrhea,  depression,  dementia, 
memory loss, sleep apnea and daytime somnolence, 
joint pains and muscle cramps, and hair loss from 
an autoimmune process directed against the hair fol-
licles. An elevated blood cholesterol level is a typical 
finding.
Objective findings in hypothyroidism are: puffy 
face and periorbital edema; cold, dry skin, which 
may be rough and scaly (the skin may appear yellow, 
but without sclera involvement); peripheral edema 
of hands and feet (typically nonpitting); thickened 
and  brittle  nails  (which  may  appear  ridged);  hair 
loss (involving the scalp, the lateral third of the eye-
brows, and, possibly, skin, genital, and facial hair); 
bradycardia; and diastolic hypertension (but blood 
pressure can be normal or even low and macroglos-
sia). The thyroid gland is mostly enlarged and firm, 
but can be of normal size or not palpable at all. 
Neurological  examination  shows  diminished 
deep  tendon  reflexes,  with  a  prolonged  relaxation 
phase, most notable at the Achilles tendons; voice 
hoarseness;  slow  speech;  cerebellar  ataxia;  and 
impairment of memory function. Patients may com-
plain of muscle aches, tenderness and stiffness (espe-
cially in the shoulders and hips), and muscle weak-
ness (mostly in the lower extremities). There are par-
esthesias from peripheral neuropathy. The possibility 
of hyponatremia from renal failure and consequent 
clinical manifestations must be considered.
Thyroid dysfunction is common in the elderly. 
The prevalence of hypothyroidism is 10% of females 
and 2% of males, while that of hyperthyroidism is 
2% in patients more than 60 years old (Rehman et 
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erly are often overlooked because they are subtle or 
even absent and are easily confused with coexisting 
illnesses, so the diagnosis is easily missed. Doctors 
should  also  think  about  the  euthyroid  sick  syn-
drome, which accompanies many diseases and does 
not respond to hormone replacement.
Clinicians should distinguish signs and symp-
toms of HE and possible thyroid disease.
Peripheral nervous system involvement
Some patients have HE and other immune diseases. 
A possible common autoimmune pathogenesis was 
supposed in a 50-year-old man with HE and motor 
neuron  disease  (Harzheim  et  al.,  2006).  He  pre-
sented with chronic progressive lower motor neu-
ron symptoms (paraparesis and fasciculations in all 
extremities)  and  encephalopathy  characterized  by 
memory and attention deficits, emotional instability, 
aggressiveness,  and  dysarthria.  Nerve  conduction 
studies and electromyography were initially normal, 
but later showed signs of lower motor neuron dis-
ease.  Both  central  and  peripheral  nervous  system 
changes improved in response to intravenous pulse 
doses of methylprednisolone followed by oral taper-
ing. Serum TPOAb also decreased.
Three case studies of peripheral neuropathy in 
HE have been published (Ferracci and Carnevale, 
2006). Clinical presentations were sensory gangli-
onopathy (Cao et al., 2005), neuralgic amyotrophy 
(Kastrup et al., 2005), and demyelinating neuropathy 
associated with symptoms of encephalopathy (Sheng 
et al., 2005). Demyelinating peripheral neuropathy is 
difficult to distinguish from chronic inflammatory 
demyelinating polyneuropathy (CIDP). 
Hashimoto encephalopathy in children
A  recent  literature  search  revealed  25  published 
reports of children diagnosed with HE aged 9-18 
years (Alink and de Vries, 2008). The most frequent 
symptoms  were  seizures  (80%),  confusion  (52%), 
headache  (40%),  hallucinations  (32%),  and  ataxia 
(36%). Deterioration of school performance can be 
one of the first signs of encephalopathy. In children, 
TPOAbs  were  demonstrated  in  all  patients  and 
TGAb in slightly over one half. Of these, 52% were 
hypothyroid  and  48%  euthyroid.  Treatment  with 
steroids was effective, with 55% of patients showing 
complete recovery. 
There are some reports of very severe clinical 
presentation of HE with psychotic manifestations. 
Progressive,  pharmacoresistant  epilepsy,  psycho-
sis, and coma were reported in a six-year-old girl 
(Hoffmann et al., 2007). Another patient, a 12-year-
old boy, had episodes of psychosis with hallucina-
tions and epilepsy (Ray et al., 2007). He had signs 
of hypothyroidism and responded well to thyroxin 
alone.
The course of HE
The  onset  of  HE  can  be  acute  or  gradual,  and 
the  further  course  can  be  with  remissions  and 
relapses  or  progressive,  with  possible  overlaps  of 
these two types (Tamagno et al., 2006). The men-
strual  cycle  can  be  associated  with  exacerbations 
in  some  cases.  Spontaneous  remissions  are  pos-
sible even in patients of advanced age with cogni-
tive  deterioration  and  stroke-like  episodes  (Katoh 
et  al.,  2007).  Responsiveness  to  corticosteroids  is 
frequent (Mocellin et al., 2007). Most patients with 
HE require hospitalization during the acute phase 
because of the severity of their deficits (Castillo et 
al., 2006). There are cases of steroid unresponsive-
ness  and  a  few  patients  died  (Fatourechi,  2005; 
Striano  et  al.,  2006).  A  27-year-old  woman  died 
after a several-month course of HE with myoclonus, 
depression, psychosis, and convulsive status epilep-
ticus not responding to therapy (Striano et al., 2006). 
The patient died of cardiac failure. Autopsy revealed 
no  vasculitic  changes.  Interestingly,  relapses  and 
recurrence of symptoms seem not to be a sign of 
ineffectiveness of steroid treatment. Duration of the 
disease according to earlier studies ranges between 
2 and 25 years.
PATHOGENESIS
The pathogenesis of HE is not known. The most 
plausible hypotheses are autoimmune vasculitis and 
reversible  leukoencephalopathy  with  a  common 
antigen in the thyroid and brain. Antibodies of the 
TGAb  and/or  TPOAb  type  are  always  found,  but HASHIMOTO ENCEPHALOPATHY 387
their role in HE is still not proved. The presence 
of antithyroid autoantibodies in the CSF might be 
a result of blood brain barrier leakage or intrathe-
cal  synthesis.  The  TPO  antibody  is  a  common 
marker of autoimmunity not only in HT, but also in 
most  autoimmune  neurological  disorders,  includ-
ing  paraneoplastic  and  nonparaneoplastic  limbic 
encephalitis  (Castillo  et  al.,  2006).  Anti-TSH,  a 
thyroid-stimulating  and  cytotoxic  antibody,  can 
also be found in HT. A small percentage of patients 
with HT (10-15%) may be antibody-negative. It is 
supposed that in HE antibodies attack neurons in 
the brain. Anti TPOAbs in high titers were detected 
in the cerebrospinal fluid (CSF) of HE patients, but 
not in controls (Blanchin et al., 2007). In that study, 
TPOAbs reacted with monkey cerebellar cells and 
normal  human  astrocytes  from  primary  cultures, 
suggesting  a  role  for  these  autoantibodies  in  the 
pathogenesis of HE. 
Some other etiological factors have been suggest-
ed, such as hypothyroidism itself, humoral factors, 
antigen-antibody complexes, vasculitis, demyelinat-
ing processes with disseminated encephalomyelitis, 
intrathecal thyroid antibodies, and global cerebral 
hypoperfusion  (Castillo  et  al.,  2006;  Tamagno  et 
al., 2006). Hypothyroidism is less likely to be the 
dominant etiology because HE patients can be not 
only hypothyroid, but euthyroid and even hyperthy-
roid. Other antibodies have been found in sera of 
these patients, and some have a pathogenetic role, as 
already mentioned. Evidence for dominant vascular 
involvement  (cerebral  hypoperfusion  and/or  vas-
culitis) is scarce. Some cases that were HE-like and 
did not respond to corticosteroids were ultimately 
confirmed at autopsy as prion disease.
Elevated  brain  thyrotropin-releasing  hormone 
(TRH) can be the cause of seizures and tremor (Ishii 
et al., 2000). Immune mechanisms are thought to 
be important rather than hormonal changes, as a 
similar  clinical  picture  can  be  seen  in  euthyroid, 
hyperthyroid,  or  hypothyroid  patients.  Transient 
hyperthyroidism secondary to increased T4 and T3 
levels resulting from thyrocyte destruction can eas-
ily be overlooked, and much more pronounced signs 
of hypothyroidism are obvious with rapid disease 
progression. In many patients, the presentation may 
be subclinical and found during routine screening 
of thyroid function. The usual finding is an elevated 
TSH level reflecting the early compensatory increase 
to maintain a nearly normal thyroid function.
There  is  some  vasogenic  edema  that  can  be 
demonstrated  occasionally  and  may  be  the  rea-
son for favorable effects of corticosteroid therapy. 
Edema can be a result of cerebral vasculitis (Ferracci 
and Carnevale, 2006). There are some similarities 
to acute demyelinating encephalomyelitis (ADEM) 
with  perivascular  lymphocytic  infiltration.  Alpha-
enolase  has  been  found  as  an  autoantigen  in  HE 
patients, but not in controls including patients hav-
ing  HT  without  neurological  symptoms  (Ochi  et 
al., 2002; Yoneda et al., 2007). Alpha-enolase is an 
antigen of the thyroid and the brain, being concen-
trated in endothelial cells and so a possible brain 
target. Autoantibodies against the amino terminal 
of alpha-enolase are a useful diagnostic marker of 
Hashimoto's  encephalopathy.  Anti  alpha-enolase 
antibodies have a high prevalence (68%) and high 
specificity in patients with HE. A humoral antineu-
ral antibody was found in a patient with HE, but 
not in HT without HE (Oide et al., 2004). This anti-
body reacts with the 36-kDa protein obtained from 
human cerebral cortex.
Autoimmune  etiology  is  further  suggested  by 
the  fact  that  some  patients  have  another  autoim-
mune disorder, for example myasthenia gravis, per-
nicious  anemia,  systemic  lupus  erythematosus,  or 
diabetes mellitus (Schäuble et al., 2003). Triphasic 
and atypical triphasic waves are sometimes present 
in HE, which is a non-specific characteristic in dif-
ferent types of encephalopathies.
Another proof of immune-mediated process is 
good response to corticosteroids and other immu-
nosuppressive therapy in the majority of patients. 
The disorder is more common in women. There is 
a possible genetic predisposition, since in most of 
the patients in one series there were HLA B8 DRw3 
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with autoimmune diseases in general and not spe-
cific for HE. 
The role of undetectable levels of hypocretin-1 
in the CSF of patients with disturbance of conscious-
ness is possible (Castillo et al., 2004). Hypocretin-
1-secreting  hypothalamic  neurons  modulate  con-
sciousness. Lowered hypocretin-1 levels can also be 
secondary to arousal changes, and no autoantibod-
ies against this antigen have been documented.
It is possible that HE will be classified as non-
vasculitic  autoimmune  inflammatory  meningo-
encephalopathy  (NAIM)  with  limbic  encephalitis 
associated  with  voltage-gated  potassium  channel 
antibodies and Sjogren encephalopathy (Josephs et 
al., 2004; Mocellin, 2007).
DIAGNOSIS
Antithyroid antibodies
Diagnosis of HE is based on the presence of neuro-
logical and neuropsychiatric symptoms and elevated 
serum antithyroid antibodies: TGAb and/or TPOAb 
and occasionally antibodies blocking the TSH recep-
tor. Positive thyroid antibodies are a frequent finding 
in the general population, with prevalence of nearly 
10%  increasing  with  advanced  age,  so  their  exact 
pathogenetic role is unclear. Antithyroid antibodies 
are found in serum of all patients, TPOAb in 100%, 
and TGAb in 70% (Mocellin et al., 2007).
Antibody titers do not always correlate with the 
stage of the disease and the therapeutical response 
(Ferracci and Carnevale, 2006). Patients can be eu-, 
hypo-,  or  hyperthyroid  (Seipelt  et  al.,  1999).  The 
thyroid  gland  can  be  goitrous,  atrophic,  or  nor-
mal in size. Recently, serum autoantibodies against 
the amino (NH2) terminal region of alpha-enolase 
(NAE) have been suggested as a useful diagnostic 
marker of Hashimoto’s encephalopathy (Fujii et al., 
2005).
Cerebrospinal fluid
Antithyroid  antibodies  can  also  be  demonstrated 
in the CSF in cases of HE, but not all of them. In 
control patients, there were no elevated TGAb nor 
TPOAb CSF titers (Ferracci et al., 2003; Blanchin et 
al., 2007). In some patients, elevated antibody titers 
can  be  partially  due  to  blood/brain  barrier  leak-
age,  but  other  studies  confirmed  synthesis  within 
the central nervous system (CNS) (Ferracci et al., 
2004). Thus, CSF antithyroid antibody titers might 
represent a useful diagnostic marker in HE patients, 
and this index usually correlates well with disease 
activity. Antithyroid antibodies are undetectable in 
patients with autoimmune thyroiditis or other neu-
rological disorders (Katoh et al., 2007). 
Cerebrospinal fluid findings more often involve 
elevated protein content (in the majority of patients) 
than lymphocytic pleocythosis (Castillo et al., 2006). 
Pleocythosis can be up to 170 cells/mm3 and mild 
hyperproteinorrachia up to 1.8 g/L (Seipelt et al., 
1999). Other potential diagnostic autoantibodies are 
also mentioned, but more extensive series of patients 
are  lacking.  Neuron-specific  enolase  and  14-3-3 
protein levels in the CSF are normal (Castillo et al., 
2006). The rate of IgG synthesis is seldom elevated, 
the IgG index is normal, and in a few patients oli-
goclonal bands were found (Castillo et al., 2006). 
Clinicians should be aware of the fact that normal 
CSF protein levels, normal cell counts and IgG syn-
thesis rates, and absence of oligoclonal bands do not 
exclude a diagnosis of HE.
Neuroimaging
Magnetic resonance imaging (MRI) reveals normal 
findings or mild brain atrophy and sometimes focal 
or  diffuse  hyperintensities  in  the  cerebral  white 
matter  and  meningeal  enhancement  (Castillo  et 
al., 2006). Cerebellar atrophy is rare. In myelopathy 
cases, there were no pathological MRI findings on the 
spinal cord. Rare patients underwent MR angiogra-
phy (MRA) of MRI spectroscopy. One patient with 
a diffuse clinical picture showed transient narrowing 
of both middle cerebral arteries on MRA consistent 
with cerebral hypoperfusion (Isik et al., 2001). In 
one patient, MRI spectroscopy demonstrated reduc-
tion of N-acetylaspartate (NAA) (a marker of the 
integrity  of  neurons)  and  an  increase  in  choline-
containing compounds (a marker of myelin sheath 
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2004).  Pathological  findings  returned  to  normal 
after steroid treatment.
Single photon emission computed tomography 
(SPECT)  yielded  both  normal  and  pathological 
findings,  with  areas  of  reduced  perfusion  in  the 
cerebral cortex and basal ganglia (Fatourechi, 2005). 
Some patients have global hypoperfusion (Ferracci 
and Carnevale, 2006). In patients with HT and no 
clinical sign of cerebral involvement, SPECT showed 
impaired cerebral perfusion (Zettinig et al., 2003). 
Cerebral angiography is generally normal (Castillo 
et al., 2006).
Positron emission tomography (PET) with 18 F-
fluorodeoxyglucose (FDG-PET) in a female patient 
with  HE  and  hyperthyrosis  revealed  diffuse  non-
uniform  cortical  hypometabolism  consistent  with 
encephalopathy  (Seo  et  al.,  2003).  Clinically,  she 
presented subacute progressive dementia, multifocal 
myoclonus, and raised levels of antithyroid autoan-
tibodies.  In  contrast  to  FDG-PET,  MRI  findings 
were normal. The patient improved in response to 
high doses of corticosteroids (dexamethasone and 
then methylprednisolone followed by prednisolone 
tapering), and eventually both cognitive status and 
PET findings became normal.  
Electroencephalography
Electroencephalography  (EEG)  shows  slowing  of 
background activity and slow waves that reflect the 
degree of severity of the underlying encephalopathy 
in  practically  all  patients  (Schäuble  et  al.,  2003). 
Slow waves are mostly in the delta range and can be 
continuous, intermittent, diffuse, or focal. A num-
ber  of  patients  have  only  moderate  slowing.  The 
EEG can also be normal in HE, and pathological 
findings  are  not  specific.  Despite  frequent  occur-
rences of seizures, epileptiform discharges are rarely 
described. The EEG findings often show improve-
ment  that  parallels  improvement  of  the  clinical 
condition (Castillo et al., 2006). Periodic triphasic 
waves suggestive of CJD were never recorded, but 
atypical triphasic waves on a slow background were 
observed  in  some  patients  (Schäuble  et  al.,  2003; 
Ferracci and Carnevale, 2006). As myoclonic jerks 
do not appear to have an EEG correlate, it was sug-
gested that myoclonus in HE has a spinal and not a 
cortical origin. 
Other findings
The  erythrocyte  sedimentation  rate  is  mildly  to 
moderately elevated in one fourth of patients, the 
C-reactive protein level is elevated in one third, and 
about a half have elevation of serum aminotransfer-
ase levels (Castillo et al., 2006). Antinuclear antibod-
ies, rheumatoid factor, and anti-gliadin antibodies 
can be detected in some patients.
Histopathological  examination  of  brain  tissue 
obtained at autopsy or brain biopsy has identified 
lymphocytic  infiltration  around  small  arterioles 
and venules of the leptomeninges and parenchyma 
(Chong  and  Rowland,  2006).  Lymphocytes  were 
predominantly of the T-type. At least one patient 
had  normal  biopsy  findings  (Fatourechi,  2005). 
Brain biopsy is indicated in steroid non-responders 
with deteriorating and atypical clinical features, but 
is not specific and frequently not a safe procedure.
Diagnostic criteria
The first set of criteria for the diagnosis of HE was 
published  by  Peschen-Rosin  et  al.  (1999).  These 
criteria  encompassed  unexplained  occurrence  of 
relapsing myoclonus, generalized seizures, psychi-
atric disorders or focal neurological deficits, three 
conditions of abnormal EEG, elevated thyroid anti-
bodies, elevated CSF protein, excellent response to 
steroids, and unrevealing cerebral MRI. Since this 
early proposal, the clinical range of symptoms and 
signs has been greatly widened, and the response 
to  steroids  has  been  shown  to  vary  substantially. 
These criteria also underestimate the significance of 
raised levels of antithyroid antibodies, which are a 
hallmark of HE. 
Ferracci and Carnevale (2006) summarize the 
diagnostic  principle  followed  by  the  majority  of 
authors: after other diagnoses have been ruled out, 
elevated  serum  antithyroid  antibodies  support  a 
diagnosis of HE, but are not confirmatory. The pres-
ence of HT is not necessary for the diagnosis of HE, D. PAVLOVIĆ ET AL. 390
as some patients have elevated autoantibodies and 
brain disease without autoimmune thyroiditis. 
The  usual  cluster  of  findings  associated  with 
HE  includes  recurrent  neurological  illness  mostly 
presented as generalized seizures, myoclonus, ataxia, 
cognitive  defects,  focal  neurological  defects,  and 
other  signs;  high  levels  of  antithyroid  antibodies; 
non-specific EEG changes; non-specific MRI white 
matter changes; elevated CSF proteins; and possibly 
abnormal thyroid functional tests (Karadeniz et al., 
2005).
Castillo  et  al.  (2006)  expanded  the  diagnostic 
criteria to a set of seven: (1) encephalopathy mani-
fested  as  cognitive  impairment  and  one  or  more 
of  the  following:  neuropsychiatric  features  (e.g., 
hallucinations, delusions, or paranoia), myoclonus, 
generalized  tonic-clonic  or  partial  seizures,  and 
focal neurological deficits; (2) the presence of serum 
thyroid antibody; (3) euthyroid status (serum sensi-
tive  thyroid-stimulating  hormone  [TSH],  0.3-5.0 
mIU/L)  or  mild  hypothyroidism  (serum  sensitive 
TSH, 5.1-20.0 mIU/L) that would not account for 
encephalopathy;  (4)  no  evidence  in  blood,  urine, 
or CSF analyses of an infectious, toxic, metabolic, 
or neoplastic process; (5) no serologic evidence of 
the  neuronal  voltage-gated  calcium  channel,  volt-
age-gated potassium channel, or other currently rec-
ognized  paraneoplastic  autoantibodies  to  indicate 
another diagnosis; (6) no findings in neuroimaging 
studies  indicating  vascular,  neoplastic,  or  other 
structural  lesions  to  explain  the  encephalopathy; 
and  (7)  complete  or  near  complete  return  to  the 
patient’s neurological baseline status following cor-
ticosteroid treatment. These criteria do not take into 
account rare cases of spinal cord involvement, HE 
with  hyperthyroidism,  or  steroid  non-responders. 
The new feature of these criteria is the exclusion of 
paraneoplastic auto-antibodies.
Another set of clinical criteria is proposed for 
the diagnosis of defined, probable, or possible HE 
(Tamagno et al., 2006). The required criteria are: (1) 
acute or subacute onset of neurological/psychiatric 
symptoms in the absence of other possible causes; (2) 
exclusion of other known causes of encephalopathy 
(i.e., bacterial, viral, or fungal infections, metabolic 
encephalopathy, Creutzfeldt-Jacob disease, etc.); (3) 
association with clinical or subclinical autoimmune 
thyroid disease; (4) serum thyroid hormone levels 
unable to justify the symptoms and persistence (or 
presentation) of symptoms or concomitant normal 
thyroid hormones; and (5) clinical response to cor-
ticosteroids. Other criteria are: elevated antithyroid 
autoantibodies levels in serum and/or CSF, hyper-
proteinorachia without pleocythosis, and unspecific 
EEG abnormalities. Defined HE should have all of 
the above mentioned criteria. For the diagnosis of 
probable HE one should have the required criteria 
plus one of the other criteria, and for possible HE 
only the required criteria are needed. These criteria 
do  not  recognize  cases  without  autoimmune  thy-
roid  disease  and  occasional  pleocythosis,  and  the 
required criteria do not include the presence of the 
autoantibodies that actually define this disease.
DIFFERENTIAL DIAGNOSIS
All  other  conditions  leading  to  encephalopa-
thy  should  be  excluded  in  order  to  diagnose  HE 
(Karadeniz et al., 2005). Typical diseases that should 
be considered are Creutzfeldt-Jakob disease, stroke, 
dementia  from  various  causes,  Wilson's  disease, 
Pick's disease, brain cancer, and primary progres-
sive  aphasia,  but  also  (less  frequently)  metabolic 
disorders, paraneoplastic disorders, cerebral vascu-
litides,  infectious  encephalopathies  (meningitis  or 
encephalitis),  demyelinating  and  primary  degen-
erative CNS diseases, paraneoplastic or idiopathic 
limbic  encephalitis,  primary  CNS  angiitis,  auto-
immune  lymphocytic  hypophysitis,  and  periph-
eral neuropathies of unexplained origin (Fatourechi, 
2005; Castillo et al., 2006; Ferracci and Carnevale, 
2006; Pavlović, 2008). 
In some instances, there are other autoimmune 
disorders present, such as diabetes mellitus type 1, 
systemic lupus erythematosus, Crohn disease, sicca 
syndrome,  primary  Sjogren  syndrome,  subacute 
combined  degeneration,  and  pernicious  anemia 
(Chong  et  al.,  2003).  These  diseases  can  either 
mimic or accompany HE. There is one reported case 
of encephalopathy in myasthenia gravis that poses 
further questions about specificity of various auto-
antibodies. A clinician should keep in mind possible HASHIMOTO ENCEPHALOPATHY 391
autoimmune etiology in unexplained encephalopa-
thies.
An important issue is differentiating HE from 
“myxedematous  madness“,  as  hypothyroidism 
is  frequently  comorbidity  (Garrard  et  al.,  2000). 
“Myxedematous  madness“  responds  well  to  thy-
roxin supplementation, while HE is usually steroid-
responsive.  Also,  many  other  psychiatric  diseases 
should be included in differential diagnosis of HE, 
psychosis,  depression,  bipolar  affective  disorder, 
and personality disorders among others (Kinrys and 
Bostwick, 2001; Müssig et al., 2005; Mocellin et al., 
2007).
THERAPY
Corticosteroids  (methylprednisolone,  dexametha-
sone,  or  prednisone)  and/or  cytostatics  (azathi-
oprine,  methotrexate,  cyclophosphamide)  in  the 
usual doses are the main therapeutic agents. There 
is  no  prefered  type  of  steroid,  dose,  or  schedule. 
Most patients respond well to steroid therapy, so it 
is the prefered initial choice. Some authors recom-
mend  a  high  dose  methylprednisolone  initially: 
one gram intravenously for 3-5 days (Castillo et al., 
2006).  After  initial  high  doses,  progressive  taper-
ing is suggested until withdrawal of the drug after 
6-12 months, depending on clinical evolution and 
responsiveness (Tamagno et al., 2006) [28], but in 
some of our cases prolonged combined treatment 
courses for several years were necessary.
There  are  some  occurrences  of  spontaneous 
remission. According to a recent analysis of pub-
lished cases and case series, 42 patients on steroid 
therapy recovered without relapses, 38 relapsed or 
had no effect, 11 patients improved with residual 
deficits, and 19 had spontaneous improvement, of 
which 14 relapsed and five remained stable (Ferracci 
and  Carnevale,  2006).  The  course  after  treatment 
differs, ranging from improvement (normal or with 
residual impairments) to chronic disease with fluc-
tuations. 
A  few  patients  were  treated  with  intravenous 
immunoglobulins (IVIG) and a combination of cor-
ticosteroids and azathioprine or cyclophosphamide. 
Some  steroid-resistant  patients  responded  well  to 
IVIG (Jacob and Rajabally, 2005). A small number 
of  patients  were  treated  with  plasmapheresis  and 
showed improvement of cognitive status and reduc-
tion of circulating antithyroid antibodies, confirm-
ing  the  autoimmune  mechanism  of  HE  (Nagpal 
and Pande, 2004; Nieuwenhuis et al., 2004; Hussain 
et al., 2005). At least on theoretical grounds, good 
results of antibody removal should be expected if 
they  are  the  main  pathogenetic  factor.  There  are 
some patients who do not relapse in spite of cessa-
tion of therapy and persistently elevated antibodies.
Any  accompanying  thyroid  disease  should  be 
treated appropriately (Chong et al., 2003). There are 
some patients that improve on thyroxin supplemen-
tation, but they might have HT with hypothyroidism 
and  not  HE.  Hypothyroidism  is  characterized  by 
elevated CSF protein content and EEG changes that 
all improve with hormone therapy. It is unclear if 
patients with subclinical hypothyroidism have any 
benefit  from  levothyroxine.  As  many  HE  patients 
have  normal  thyroid  status  or  are  hyperthyroid, 
hypothyroidism  cannot  be  the  only  etiology  of 
encephalopathy.
Various  symptomatic  medications  might  be 
needed,  depending  on  the  clinical  presentation. 
Patients  with  seizures  should  receive  antiepileptic 
medication  along  with  immunosuppressive  ther-
apy,  bearing  in  mind  the  possible  side  effects. 
Neuropsychiatric symptoms should be treated with 
atypical antipsychotics and/or antidepressants. It is 
necessary, in our experience, to treat any infection 
appropriately, since patients with HE can relapse or 
develop delirium.
A currently proposed algorithm for HE includes 
methylprednisolone  intravenously,  one  gram  daily 
for  3-5  days  initially  (Marshall  and  Doyle,  2006). 
Patients who are hypothyroid should receive levo-
thyroxine  and  those  with  seizures  antiepileptic 
medication. In the event of recurrence, methylpred-
nisolone is given intravenously (1 gram daily for 3-5 
days with prednisone). When the prednisone dose 
needs to be reduced or in resistant cases, steroids are D. PAVLOVIĆ ET AL. 392
combined with azathioprine, cyclophosphamide, or 
methotrexate.
CONCLUSION
Hashimoto  encephalopathy  is  probably  less  rare 
than  is  supposed  and  is  a  treatable  condition. 
Unfortunately, HE is highly underdiagnosed, mostly 
because  of  lack  of  awareness  and  false  diagnostic 
evaluation. The clinical picture differs considerably, 
ranging from generalized to focal deficits encroach-
ing on both neurological and psychiatric signs and 
symptoms. Antithyroid autoantibodies are elevated 
in serum and in some patients in the CSF as well. 
Findings of MRI, EEG, SPECT, PET, and CSF are 
non-specific. Every effort should be made to make 
the correct diagnosis as soon as possible and start 
specific therapy. There are some diagnostic criteria, 
but none of them encompass all cases. Untreated 
HE can lead to serious brain injury with irrevers-
ible dementia and even death. The cornerstones of 
therapy  are  corticosteroids  and  sometimes  other 
immunosuppressants.  The  pathogenesis  probably 
involves autoimmune attack on cerebral vasculature 
and/or neural antigens. The course is variable, rang-
ing from acute to chronic and relapsing/remitting.
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ХАШИМОТО ЕНЦЕФАЛОПАТИЈА – НЕУРОЛОШКА И ПСИХИЈАТРИЈСКА ПЕРСПЕКТИВА
Д. М. ПАВЛОВИЋ1, АЛЕКСАНДРА М. ПАВЛОВИЋ1 И МАЈА ЛАЧКОВИЋ2
1Институт за неурологију, Клинички центар Србије, 11000 Београд, Србија
2Институт за психијатрију, Клинички центар Србије, 11000 Београд, Србија
Хашимото енﾭцефалопатија (ХЕ) је аутоимунﾭа 
болест са нﾭеуролошким и нﾭеуропсихијатријским 
испољавањима и повишенﾭим титровима анﾭтити-
реоиднﾭих анﾭтитела у серуму и цереброспинﾭалнﾭој 
течﾭнﾭости. Болеснﾭици су углавнﾭом женﾭе. Узﾭраст 
варира од 8 до 86 годинﾭа. Преваленﾭца ХЕ се про-
цењује нﾭа 2,1/100000. Неуролошки и/или психија-
тријски симптоми и зﾭнﾭаци сачﾭињавају клинﾭичﾭку 
слику.  Болест реагује добро нﾭа кортикостероид-
нﾭу терапију, али нﾭекад се мора применﾭити и дру-
га имунﾭомодулаторнﾭа терапија. Претпоставља се 
аутоимунﾭи механﾭизﾭам са анﾭтителима нﾭа анﾭтиге-
нﾭе можданﾭе коре. Ток болести може бити акутанﾭ, 
субакутанﾭ, хронﾭичﾭанﾭ и ремитенﾭтанﾭ. Неки боле-
снﾭици се опораве спонﾭтанﾭо, али има и леталнﾭих 
исхода упркос адекватнﾭој терапији. 